Selected checkpoint inhibitors in clinical testing for various cancers. Source: BCIQ: BioCentury Online Intelligence; company press releases; www.clinicaltrials.gov

Company

Product

Description

Indication

Status

Bristol-Myers Squibb Co. (NYSE:BMY)

Yervoy ipilimumab

Human mAb against CTLA-4 (CD152)

Advanced melanoma; other cancers

Mkt (melanoma); Ph I-Ph III (several cancers)

AstraZeneca plc (LSE:AZN; NYSE:AZN)/

Tremelimumab

Human mAb against CTLA-4

Hepatocellular carcinoma

Ph II

Pfizer Inc. (NYSE:PFE)

(CP-675206)

(HCC); metastatic melanoma; metastatic colorectal cancer